In fact, in several cancer types, such as NSCLC, melanoma and urothelial cancer (UC), the level of TMB has been noted to be related with the clinical outcomes; for example, the higher expression of TMB after anti-PD-1/PD-L1 or anti-CTLA-4 treatment, perhaps present better clinical performance in terms of OSRs, than lower levels of TMB (10, 53, 54). Here, CD274 is linked to melanoma.